How Much Does Peptide Therapy Cost?

Peptide therapy for anti-aging and longevity purposes typically runs $100 to $500 per month. Single compounds like sermorelin can cost as little as $40–$90 monthly. Combination protocols with growth hormone secretagogues can exceed $1,000 monthly during the initial setup phase.

Because these uses are considered elective and are not FDA-approved for anti-aging indications, insurance and Medicare do not cover them (Centers for Medicare & Medicaid Services, 2026).

The price you're quoted depends heavily on which peptide, where it's sourced, and how much physician oversight is included.

What This Means

"Peptide therapy" isn't one product with one price tag. It's a category that includes dozens of different compounds, each compounded, dosed, and priced differently.

A single peptide like sermorelin from a licensed compounding pharmacy sits at the low end. A multi-peptide protocol combining a growth hormone secretagogue with labs, an initial consultation, and monthly follow-up visits sits at the high end.

Because none of these compounds are FDA-approved for anti-aging use, there's no standardized "list price" the way there is for an approved prescription drug.

Pricing is set by individual clinics and compounding pharmacies, and it varies by region, by which pharmacy is used, and by how much clinical monitoring is bundled in.

Candidacy

Peptide therapy is generally considered by adults interested in supporting recovery, body composition, sleep quality, or age-related changes in hormone signaling. It is not for anyone with an unevaluated symptom, or the assumption that a peptide will fix a specific problem without a workup first.

Reasonable candidates typically have baseline labs reviewed and a documented medical history. They should also have no contraindicating conditions, such as:

• Active cancer
• Uncontrolled diabetes
• Pregnancy

People who are not good candidates include those seeking a peptide as a substitute for addressing an underlying, undiagnosed medical issue. This also includes those unwilling to return for the follow-up labs that responsible monitoring requires.

Clinical Evaluation

A physician-guided evaluation for peptide therapy generally includes:

• A review of symptoms and goals
• Relevant lab work (often including IGF-1, a metabolic panel, and hormone levels depending on the peptide being considered)
• A medical history and medication review
• A discussion of which compound, if any, is appropriate given that history

This evaluation step is where cost estimates diverge most from what's advertised. A quoted "$150/month" price for a peptide alone often excludes the initial consultation and lab panel, which can add $200–$600 to the first month regardless of which compound is ultimately used.

Available Options

Patients weighing peptide therapy have several paths, and peptides are not the only one:

• Compounded peptides through a licensed clinic or compounding pharmacy — the most common route, and the one this article focuses on for pricing.
• Conventional, FDA-approved alternatives for specific underlying conditions — for example, an FDA-approved growth hormone product for a diagnosed growth hormone deficiency, rather than an off-label secretagogue for general anti-aging purposes.
• Lifestyle-based approaches — sleep, resistance training, and nutrition changes, which carry no prescription cost and have the most consistent evidence base for supporting healthy aging (Cappola et al., 2023).
• No intervention, paired with routine monitoring — a legitimate choice for patients who prefer to wait for stronger evidence before paying out of pocket for an unapproved compound.

Benefits, Limitations & Risks

Benefits

Some patients report improvements in sleep, recovery, and body composition with certain peptides.

A randomized, placebo-controlled trial of a growth hormone-releasing hormone analog in healthy older adults found measurable increases in nocturnal growth hormone and IGF-1 levels, along with modest gains in muscle strength (Vittone et al., 1997).

That trial also found no significant change in body composition, weight, or metabolic markers, a reminder that reported benefits are often compound-specific and modest, not universal.

Limitations

The limitations are real. Human clinical data for most anti-aging peptides remain limited, and dosing is not standardized the way it is for an approved drug.

Because these products are compounded rather than manufactured under FDA approval, there is no guarantee of consistent purity or potency between pharmacies (U.S. Food and Drug Administration, 2026).

Risks

Several commonly marketed peptides — including ipamorelin acetate, CJC-1295, and the growth hormone-releasing peptides GHRP-2 and GHRP-6 — currently sit on the FDA's list of bulk drug substances identified as presenting potential significant safety risks in compounding.

This is based on concerns that include immunogenicity, impurities, and, in some cases, reported serious adverse events (U.S. Food and Drug Administration, 2026).

That doesn't mean every patient who uses them will be harmed. But it does mean the regulatory and safety picture is unsettled, not established.

What the Evidence Shows

What the Evidence Establishes

Evidence does establish that stimulating the growth hormone axis with a GHRH analog can measurably raise IGF-1 and growth hormone levels in older adults. It can also produce modest strength gains in short-term trials (Vittone et al., 1997).

For a differently studied peptide, BPC-157, a 2025 literature and patent review found a substantial body of preclinical (animal and cell-based) research suggesting tissue-protective and anti-inflammatory effects. But it concluded that robust human clinical trial data are still lacking (Józwiak et al., 2025).

What the Evidence Does Not Establish

Evidence does not establish that any compounded peptide reverses aging, extends lifespan in humans, or produces the outcomes often implied in direct-to-consumer marketing.

The Endocrine Society's own scientific statement on hormones and aging is explicit that no currently available intervention is approved specifically to reverse the normal, age-related decline in growth hormone secretion (Cappola et al., 2023).

Claims that go beyond what a compound's own trial data show should be treated with real skepticism, regardless of how confidently they're marketed.

Recovery / Next Steps

Peptide therapy is not a one-time procedure with a defined recovery window. It's an ongoing regimen that requires periodic reassessment.

Most physician-guided protocols include a follow-up lab draw and check-in at roughly 8–12 weeks. This confirms the compound is having the intended physiologic effect and that nothing concerning has appeared on labs.

Budgeting for that follow-up visit, not just the peptide itself, is part of estimating the real monthly cost.

Orlando Considerations

Florida does not have a state law specifically pricing or capping compounded peptide costs. Rates vary clinic to clinic across the Orlando area the same way they do nationally.

What Florida patients should know: any compounding pharmacy filling a peptide prescription, whether local or mail-order, must operate under standard 503A or 503B pharmacy rules.

A physician prescribing a compound flagged on the FDA's safety-risk list should be able to explain why, given the available alternatives (U.S. Food and Drug Administration, 2026).

Ask where the compound is sourced and whether the pharmacy is licensed in Florida before paying for a protocol.

Frequently Asked Questions

Is peptide therapy covered by insurance or Medicare?

No. Compounded peptides used for anti-aging or longevity purposes are considered elective and are excluded from Medicare and most commercial insurance coverage, since coverage generally requires an FDA-approved indication supported by medical necessity (Centers for Medicare & Medicaid Services, 2026).

Why do peptide therapy prices vary so much between clinics?

Because there’s no FDA-approved product with a standard price, each clinic sets its own pricing based on the compounding pharmacy it uses, how much lab work and physician monitoring is bundled in, and local market rates.

Is a cheaper peptide source just as good as an expensive one?

Not necessarily. Because compounded peptides aren’t FDA-approved, purity and potency can vary meaningfully between pharmacies.

A lower price from an unlicensed or overseas source carries different risk than a higher price from a licensed compounding pharmacy working with a physician (U.S. Food and Drug Administration, 2026).

Do I need labs before starting peptide therapy?

Reputable physician-guided programs include baseline labs before prescribing and follow-up labs during the course of therapy. A program that skips this step is skipping the part that actually protects you.

Are all anti-aging peptides legal to prescribe?

Not consistently. Some, including several growth hormone-related peptides, currently appear on the FDA’s list of bulk substances with identified safety concerns for compounding, which affects whether a compounding pharmacy can legally include them in a prescription (U.S. Food and Drug Administration, 2026).

References

Cappola, A. R., Auchus, R. J., El-Hajj Fuleihan, G., Handelsman, D. J., Kalyani, R. R., McClung, M., Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. (2023).

Hormones and aging: An Endocrine Society scientific statement. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1835–1874. https://doi.org/10.1210/clinem/dgad225

Centers for Medicare & Medicaid Services. (2026). Local coverage determination: Cosmetic and reconstructive surgery (L39506). U.S. Department of Health and Human Services.

Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—Literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185

U.S. Food and Drug Administration. (2026, April 22). Certain bulk drug substances for use in compounding that may present significant safety risks.

Vittone, J., Blackman, M. R., Busby-Whitehead, J., Tsiao, C., Stewart, K. J., Tobin, J., Stevens, T., Bellantoni, M. F., Rogers, M. A., Baumann, G., Roth, J., Harman, S. M., & Spencer, R.

G. S. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 46(1), 89–96. https://doi.org/10.1016/S0026-0495(97)90174-8

Last medically reviewed: August 23, 2026.

Related reading

• Does Insurance Cover Hormone Replacement Therapy?
• Does Insurance Pay for Stem Cell Injections? 2026 Guide
• Does Medicare Cover Regenerative Medicine?
• Is Regenerative Medicine Covered by Insurance?
• What a Peptide Specialist Actually Does

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.